News Valeo Pharma Inc. Canadian Securities Exchange

Equities

VPH

CA91915B1085

Delayed Canadian Securities Exchange Other stock markets 03:57:37 2022-03-28 pm EDT			5-day change	1st Jan Change
0.66 ^CAD	-.--%		+1.54%	-10.81%

Mar. 22	Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	CI
Mar. 15	Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE	Apr. 09	AQ
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS	Mar. 25	AQ
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS	Mar. 22	AQ
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	Mar. 22	CI
Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024	Mar. 15
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS	Mar. 14	AQ
Valeo Pharma Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 14	CI
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL, WEBCAST	Mar. 08	AQ
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST	Mar. 07	AQ
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES	Feb. 13	AQ
Valeo Pharma Inc. Announces Board Changes	Feb. 13	CI
Valeo Pharma Brief: Notes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024	Feb. 02	MT
Valeo Pharma Brief: Says Proceeds from reimbursement to be used for debt reduction purposes	Feb. 02	MT
Valeo Pharma Brief: Adding SIMBRINZA remains under Valeo Pharma exclusive promotion and distribution	Feb. 02	MT
Valeo Pharma Brief: Says Original commercialization and supply agreement amended following global divestment of XIIDRA	Feb. 02	MT
Valeo Pharma Brief: Amending Agreement With Novartis Pharmaceuticals Canada For XIIDRA In Canada, and Credit Facility With Sagard Healthcare Royalty Partners, LP	Feb. 02	MT
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP	Feb. 02	AQ
Valeo Pharma Amends Agreement with Novartis Pharmaceuticals Canada for (Pr)XIIDRA in Canada	Feb. 02	CI
Valeo Pharma Inc. Amends Credit Facility with Sagard Healthcare Partners, LP	Feb. 02	CI
Transcript : Valeo Pharma Inc., Q4 2023 Earnings Call, Jan 30, 2024	Jan. 30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Valeo Pharma Inc. Canadian Securities Exchange

Equities

VPH

CA91915B1085

Summary

Filters